

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on February 2, 2004.

Richard S. Echler, Sr. 41006
Name of Attorney/Agent Registration No.
Signature of Attorney or Agent



P&G Case 9071M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Frank Hallock Ebetino et al. : Confirmation No.
Serial No. 10/689,022 : Group Art Unit
Filed 10/20/2003 : Examiner

For MELANOCORTIN RECEPTOR LIGANDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in § 1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. § 1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. § 1.56(b).

1. ☐ 37 C.F.R. § 1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. § 1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

☒ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ____, filed ____. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (4) Copies of all said documents, except Cite Numbers ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed ____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By

Richard S. Echler, Sr.

Attorney or Agent for Applicant(s)

Registration No. 41,006


(513)622-1825

Date: February 2, 2004

Customer No. 27752

(IDS.doc) (Last Revised 10/10/03)

Please type a plus sign (+) inside this box → [+]



PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

COMPLETE IF KNOWN	
Application Number	10/689,022
Confirmation Number	
Filing Date	10/20/2003
First Named Inventor	Frank Hallock Ebetino
Group Art Unit	
Examiner Name	
Attorney Docket Number	9071M

SHEET 1 of 2

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-5,783,582	07/21/1998	Guo et al.	
	2	US-5,804,578	09/08/1998	Chakravarty et al.	
	3	US-5,721,250	02/24/1998	Morriello et al.	
	4	US-5,494,919	02/27/1996	Morriello et al.	
	5	US-5,721,251	02/24/1998	Chen et al.	
	6	US-5,880,125	03/09/1999	Nargund	
	7	US-5,965,565	10/12/1999	Chen et al.	
	8	US-5,536,716	07/16/1996	Chen et al.	
	9	US-6,350,760 B1	02/26/2002	Bakshi et al.	
	10	US-5,492,916	02/20/1996	Morriello et al.	
	11	US-5,877,182	03/02/1999	Nargund et al.	
	12	US-5,936,089	08/10/1999	Carpino et al.	
	13	US-6,294,534 B1	09/25/2001	Nargund et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	14	WO 01/70337 A1	09/27/2001	Palucki et al.		
	15	WO 96/13265 A1	05/09/1996	Nargund et al.		
	16	WO 96/02530 A1	02/01/1996	Guo et al.		
	17	WO 94/19367 A1	09/01/1994	Chen et al.		
	18	WO 03/031410 A1	04/17/2003	Neurocrine Biosciences, Inc.		
	19	WO 94/13696 A1	06/23/1994	Chen et al.		
	20	WO 99/64002 A1	12/16/1999	Nargund et al.		
	21	WO 98/10653 A1	03/19/1998	Nargund et al.		
	22	WO 02/00654 A1	01/03/2002	Carpino et al.		
	23	WO 01/91752 A1	12/06/2001	Bakshi et al.		
	24	WO 99/58501 A1	11/18/1999	Hansen et al.		
	25	WO 96/38471 A1	12/05/1996	Carpino et al.		
	26	WO 96/38471 A1	08/01/2002	Backer et al.		
	27	WO 02/059107 A1	02/28/2002	Bakshi		
	28	WO 02/15909 A1	09/06/2002	Ujjainwalla et al.		
	29	WO 02/068388 A2	09/06/2002	Goulet et al.		
	30	WO 02/068387 A2	09/06/2002	Bakshi et al.		
	31	WO 00/74679 A1	12/14/2000	Basu et al.		
	32	WO 99/55679 A1	11/04/1999	Briner et al.		
	33	WO 02/059117 A1	08/01/2002	Yu et al.		
	34	WO 02/070511 A1	09/12/2002	Palucki et al.		
	35	WO 01/70708 A1	09/27/2001	Neurocrine Biosciences, Inc.		
		WO 03/031410 A1	04/17/2003			
EXAMINER				DATE CONSIDERED		



-2-

EXAMINER's reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.